1. Mitochondria-related TFAM gene variants and their effects on patients with cervical cancer
- Author
-
Egle Ziliene, Juste Cepaite, Elona Juozaityte, Rasa Ugenskiene, Arturas Inciura, Ieva Golubickaite, and Lina Poskiene
- Subjects
Oncology ,Cervical cancer ,medicine.medical_specialty ,Oncogene ,business.industry ,cervical cancer ,General Neuroscience ,Cancer ,Single-nucleotide polymorphism ,General Medicine ,Articles ,TFAM ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,mitochondrial transcription factor A ,single nucleotide polymorphism ,Internal medicine ,Genotype ,medicine ,SNP ,tumor phenotype ,General Pharmacology, Toxicology and Pharmaceutics ,business ,Genotyping - Abstract
Cervical cancer is the fourth most common type of cancer in women worldwide, with high incidence and mortality rates, particularly in developing countries. There are human papillomavirus vaccines and cytological screening programs available; however, there are no molecular markers that would aid the prognosis of the course of the disease or prediction of the outcomes of the patients. The aim of the present study was to investigate the associations between single nucleotide polymorphisms (SNPs) of the mitochondrial transcription factor A (TFAM) gene (rs11006132, rs11006129, rs1937, rs16912174, rs16912202 and rs3900887), and the clinical parameters and tumor phenotype of patients with cervical cancer. DNA isolated from patients with cervical cancer (n=172) was used for genotyping using Real-Time PCR using TaqMan probes. It was revealed that the TFAM rs3900887 TT and AT genotypes were associated with a lower risk of developing larger tumors. The results showed an association between the rs3900887 SNP and tumor phenotype, indicating TFAM rs3900887 as a potential biomarker for tumor size in cervical cancer.
- Published
- 2021